BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$

[JohnJohnson]

[b]BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$

[JohnJohnson]

BMSN $ NEWS - BMSN will shoot over 0,10 after FDA Approval $$$

sierraworldequityreview.blogspot.de/2013/03/new-price-targetbio-matrix-scientific_2.html?m=1

$$$ Alert__BREAKING>>>>Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.

Sierra World Equity Review

Saturday, March 2, 2013
New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review
HEADLINE: New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review.

For the latest updates on these stocks and to learn more about Sierra go to:

Sierra's Hot Stock Website
2013 FDA Calender
Latest Clinical Trial Results

A list of all Sierra's accurate calls and predictions that came true:
All These Came True, Accurate Sierra Are You Believer Yet!!!

Accurate call after accurate call, smart, single supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 9 months than all other Stock Reviews COMBINED.
Check back for instant updates....Independent Sierra World Equity Review currently hold no positions in any of the stocks listed above......be the first to read Sierra's new posts, follow Sierra on Twitter
Sierra World Equity Review at 1:02 AM

BMSN $ STRONG BUY $ Target: 1,00+ US Dollars

< Message edited by Bullrider77 -- 3/2/2013 3:40:26 PM >

[JohnJohnson]

BMSN - FDA NEWS SOON $ Strong Buy $$$

[JohnJohnson]

BMSN..BMSN..BMSN..
Penny Stock Experts Blog - blog.todayspickis.com: Stocks To Watch 03/06/13 - BMSN Penny Stock Experts Blog - blog.todayspickis.com: Stocks To Watch 03/06/13 - BMSN

BMSN - Momentum/Breakout Watch - (Bio-Matrix Scientific Group Inc.) - closed up 42.55%, at .0134c a share, on over 84.11 million shares traded today. Shares traded sideways this morning, before rallying up to .0138c a share, and closing slightly lower at .0134c. The stock showed impressive strength this afternoon which leads us to believe the stock could move higher into tomorrow and over the coming days. Look for a break and close above .015c to signal a further breakout. Keep it on close watch.

BMSN..BMSN..BMSN..BMSN..BMSN..

[JohnJohnson]

[b]BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$

[JohnJohnson]

[JohnJohnson]

[b]BMSN - MEGA NEWS $$$ $$$ Regen BioPharma Receives IND # From FDA for HemaXellerate
Print
Alert
Bio-matrix Scientific Group, Inc. (PL) (USOTC:BMSN)
Intraday Stock Chart

Today : Monday 18 March 2013
Click Here for more Bio-matrix Scientific Group, Inc. (PL) Charts.

Regen BioPharma, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today issuance of IND number 15376 for its proposed Phase I/II clinical trial evaluating use of its stem cell product, HemaXellerate, for treatment of aplastic anemia.

As part of the clinical trial approval process, the FDA will issue comments on the proposed trial which must be addressed to the FDA's satisfaction before patient dosing is initiated. The clinical trial will treat ten patients with aplastic anemia that have not responded to conventional therapy and lack a bone marrow donor.

"We are pleased that the company has been issued an IND number and has taken the first step towards regulatory approval in the USA," said David Koos, Chairman & CEO of Bio-Matrix. "We have compiled an internationally-renowned team, consisting of corporate and academic partners, which cover the manufacturing, regulatory, and medical aspects of the project. Members of the team have previously published with Regen the scientific rational for the trial in a peer-reviewed publication in January of last year which may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf."

HemaXellerate is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. If the clinical trial is successful, the company plans to expand use of HemaXellerate